MyHealthTeam Launches myMASHteam To Help Increase Patient Awareness and Education
Medically reviewed online content, real patient stories, and support for people living with metabolic dysfunction-associated steatohepatitis (MASH)
SAN FRANCISCO, CA/August 28, 2024 — MyHealthTeam, creator of the largest and fastest growing patient communities for people facing chronic health conditions, today announced the launch of myMASHteam. This new website and patient community is dedicated to people diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). It provides medically reviewed articles and resources on symptoms and potential treatments, and it offers guidance for talking with doctors and an ability to ask questions and learn from others in the community.
Visit myMASHteam at: www.mymashteam.com
MASLD and MASH are caused by the buildup of liver fat unrelated to alcohol consumption. Recently, health experts agreed to rename nonalcoholic fatty liver disease (NAFLD) to MASLD. Nonalcoholic steatohepatitis (NASH) is now known as MASH.
It is estimated that 25 percent of the world’s population has MASLD, and about 1 in 5 people (around 20 percent) of people with MASLD eventually develop MASH. It’s important to be able to tell the difference between MASLD and MASH, as people with MASH are at a higher risk of progressing to advanced scarring of the liver. In fact, MASH is quickly becoming one of the leading causes of liver transplants in the United States.
Although there is no known cause for MASLD or MASH, certain risk factors raise the chances of developing them. Risk factors include being age 40 and older, having a high Body Mass Index (BMI) score, eating a diet high in fructose, and having high cholesterol or lipid (blood fat) levels, metabolic syndrome, certain hormone disorders, or low thyroid hormone levels. Genetics may also play a role in the risk of MASLD and MASH. Researchers haven’t identified any specific genes that cause MASH, but certain genes may affect the severity of the disease. Additionally, they have found that people in certain racial and ethnic groups are more likely to develop MASLD.
“We are pleased to create a much-needed social network for people living with MASH and MASLD,” said Eric Peacock, co-founder and CEO of MyHealthTeam. “As MASLD and MASH are difficult to diagnose, many people don’t show symptoms until their disease has progressed. All the more reason for us to raise awareness and help people gain the support and medically reviewed information they need to help identify their risk and take measures to avoid progression that could lead to liver damage.”
The new site, myMASHteam, includes:
- Medically approved information about the condition, including symptoms, causes, treatments, and testing options
- Insights and education on promising new diagnostic and treatment therapies
- Real patient stories and portraits of people from diverse backgrounds who live with these conditions offering tips, support, and personal stories (launches October 2024)
- Community, conversation, and support from people with the same diagnosis
- Guidance on managing MASLD and MASH
This will be MyHealthTeam’s 60th patient community dedicated to a chronic condition or rare disease. The company’s communities help more than 20 million people each year.
About MyHealthTeam
MyHealthTeam believes that if you are diagnosed with a rare disease or chronic condition, it should be easy to find the people, support, and medically approved information you need to best manage your condition. Millions of people regularly visit one of the 60 condition-based patient communities by MyHealthTeam — from Alzheimer’s to vitiligo — covering all therapeutic areas and many rare conditions in between. Visit MyHealthTeam for a complete list of conditions served. MyHealthTeam patient communities are actively being used in 13 countries.
CONTACT